Eight companies spearheading CRISPR technology
This issue of our newsletter is supported by Cryoport Systems.
CRISPR has rapidly become one of the most powerful tools in genetic engineering, enabling precise changes to DNA.
As CRISPR technology progresses, companies leveraging it are now seeing more and more success in the clinic - and the market is growing.
Recent leaps in the field include CRISPR Therapeutics and Vertex Pharmaceuticals’ collaborative success leading to CASGEVY’s approval by the FDA, and Editas Medicine’s promising efforts to treat blindness.
This week, we explore eight companies keeping the CRISPR field dynamic.
To find out more, read the full article: “CRISPR technology’s next wave: Eight companies to watch in 2024”
A MESSAGE FROM OUR SPONSOR CRYOPORT SYSTEMS
De-risk your gene therapy supply chain
Give your gene therapy the best chance of success with Cryoport Systems. Our end-to-end supply chain platform – which includes biostorage, drug labeling, robust dry ice shipping systems and shipping risk assessments – supports your research from development to delivery within a single vendor relationship for streamlined, optimized solutions that proactively mitigate risk every step of the way.
🔥 More noteworthy articles from this week:
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that can become life-threatening when paired with other metabolic diseases like diabetes. After years of failed clinical trials, U.S. regulators finally approved the first drug to tackle MASH earlier this year and more clinical advancements have now been pouring in.
There are plenty of universities throughout India offering biotech-related courses that can lead to numerous career opportunities and job prospects. In this article, we take a look at five biotechnology colleges in different regions of India that are preparing future talent to work in the nation’s life sciences industry, or elsewhere in the world.
As biopharma companies have spent hundreds of billions of dollars on M&A over the last decade, some deals didn’t quite turn out as expected for reasons varying from underwhelming drug sales to legal issues. In this article, we take a look at some of the most prominent failed acquisitions that have taken place in the biopharma scene in the last decade.
While Georgia does not count among the biggest U.S. biotech hubs, the state still has a prominent biotech scene and, with an ecosystem built around the state’s capital city, Atlanta, Georgia is home to more than 4,000 life sciences organizations. Here, we delve into the Georgia biotech landscape with seven companies to know about in 2024.
Heidelberg Pharma is a clinical-stage biotech company developing antibody drug conjugates (ADCs). Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. To tell us about how HDP-101 works, and what Heidelberg Pharma is doing in the space, we had a conversation with the company’s CEO, Prof. Andreas Pahl.
Are you looking for funding to get your innovative idea off the ground? There are a number of campaigns run by world leading R&D teams who are seeking emerging science and technology. We have a list of various current opportunities and biotech funding programs that you could take part in.
In the realm of biotechnology, the use of mammalian cell lines has emerged as a cornerstone in the production of vital biotherapeutics and vaccines. Here, we dive into the key characteristics of mammalian cell lines that have earned them their critical role in the development of biologics.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.